In human HT1080 fibrosarcoma xenograft tumors in athymic Cre nu/nu mice, daily intraperitoneal injections of 1 mg Thiabendazole significantly reduced tumor size compared with an equal volume of DMSO injected in the same manner. In C. elegans carrying cyp-35a5::GFP, Thiabendazole at 0.125 mM for 1 hour produced strong GFP expression. The same treatment produced strong GFP expression in C. elegans carrying cyp-35d1::GFP. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Thiabendazole response in fibrosarcoma xenografts
Animal study · human HT1080 fibrosarcoma xenograft tumors in athymic Cre nu/nu mice [1]
In human HT1080 fibrosarcoma xenograft tumors in athymic Cre nu/nu mice, daily intraperitoneal injections of 1 mg Thiabendazole significantly reduced tumor size compared with an equal volume of DMSO injected in the same manner.
Conditions shared by the study groups
- Route
- intraperitoneal injections
- Treatment course
- daily
- Vehicle
- 20 µl DMSO
- Thiabendazole 1 mg
- Model: human HT1080 fibrosarcoma xenograft tumors in athymic Cre nu/nu mice
Methods and source locations
Compound reported in the paper: Thiabendazole
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > In Vitro Angiogenesis Assays (S19); Materials and Methods > Cell Migration Assays (S24); Materials and Methods > Xenograft Model (S30, S31, S33, S34); Figure 8 legend (S96)
tumor volume in mm3: tumor volume in mm3; comparator: an equal volume of DMSO — Materials and Methods > Xenograft Model (S31, S34); Figure 8 legend (S96)
Thiabendazole 1 mg · Materials and Methods > Xenograft Model (S31); Figure 8 legend (S96)
Thiabendazole and intestinal reporter expression
Animal study · C. elegans; cyp-35a5::GFP [2]
cyp-35a5::GFP; thiabendazole (0.125 mM, 1 hour): GFP expression 5 (strong expression), scored on an arbitrary scale from 0 (showing no GFP expression) to 5 (showing strong GFP expression).
Conditions shared by the study groups
- Route
- 96-well plates containing 100 µl M9 buffer
- Treatment course
- 1 hour
- Vehicle
- 0.5% DMSO
- Thiabendazole 0.125 mM
- Model: C. elegans; cyp-35a5::GFP
- Reported limits: Removed after verification: value.
Methods and source locations
Compound reported in the paper: Thiabendazole
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Xenobiotic Induction of Transcripts Encoding Phase I and Phase II Metabolic Enzymes is Highly Specific (S3, S11, S13); Materials and Methods > qPCR Analyses (S41); Materials and Methods > Analysis of GFP Expression and RNAi (S78, S79); Table 1 legend (S112); Table 1 (T1.h2, T1.h3, T1.r2)
GFP expression; arbitrary scale from 0 (showing no GFP expression) to 5 (showing strong GFP expression): GFP expression; arbitrary scale from 0 (showing no GFP expression) to 5 (showing strong GFP expression); comparator: DMSO control — Materials and Methods > qPCR Analyses (S41); Materials and Methods > Analysis of GFP Expression and RNAi (S78, S79); Table 1 legend (S112); Table 1 (T1.h2, T1.h3, T1.r2)
Thiabendazole 0.125 mM · Materials and Methods > qPCR Analyses (S41); Materials and Methods > Analysis of GFP Expression and RNAi (S78); Table 1 legend (S112); Table 1 (T1.h3, T1.r2)
Thiabendazole and GFP reporter expression
Animal study · C. elegans; cyp-35d1::GFP [2]
cyp-35d1::GFP; thiabendazole (0.125 mM, 1 hour): GFP expression 5 (strong expression), scored on an arbitrary scale from 0 (showing no GFP expression) to 5 (showing strong GFP expression).
Conditions shared by the study groups
- Route
- 96-well plates containing 100 µl M9 buffer
- Treatment course
- 1 hour
- Vehicle
- 0.5% DMSO
- Thiabendazole 0.125 mM
- Model: C. elegans; cyp-35d1::GFP
- Reported limits: Removed after verification: value.
Methods and source locations
Compound reported in the paper: Thiabendazole
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > Xenobiotic Induction of Transcripts Encoding Phase I and Phase II Metabolic Enzymes is Highly Specific (S3, S11, S13); Materials and Methods > qPCR Analyses (S41); Materials and Methods > Analysis of GFP Expression and RNAi (S78, S79); Table 1 legend (S112); Table 1 (T1.h2, T1.h3, T1.r5)
GFP expression; arbitrary scale from 0 (showing no GFP expression) to 5 (showing strong GFP expression): GFP expression; arbitrary scale from 0 (showing no GFP expression) to 5 (showing strong GFP expression); comparator: DMSO control — Materials and Methods > qPCR Analyses (S41); Materials and Methods > Analysis of GFP Expression and RNAi (S78, S79); Table 1 legend (S112); Table 1 (T1.h2, T1.h3, T1.r5)
Thiabendazole 0.125 mM · Materials and Methods > qPCR Analyses (S41); Materials and Methods > Analysis of GFP Expression and RNAi (S78); Table 1 legend (S112); Table 1 (T1.h3, T1.r5)
